Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status Prescription
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
NDC Product Code 54893-0043; 68554-0088; 54893-0032; 65344-0033; 63539-044; 0069-0151; 0069-0145; 63539-026
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coronary artery restenosis24.04.04.023;;; Available
Postrenal failure20.01.03.0210.000533%Not Available
Malignant urinary tract neoplasm20.08.01.005; Available
Stress cardiomyopathy24.04.04.026; Available
Infectious pleural effusion11.01.09.011; Available
Spinal pain17.10.01.020;; Available
Skin wound23.03.11.022; Available
Clear cell renal cell carcinoma16.08.02.004; Available
End stage renal disease20.01.03.0190.001066%Not Available
Tongue discomfort07.14.02.0190.000533%Not Available
The 19th Page    First    Pre   19    Total 19 Pages